346 related articles for article (PubMed ID: 29050219)
1. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Torres-Guzmán R; Calsina B; Hermoso A; Baquero C; Alvarez B; Amat J; McNulty AM; Gong X; Boehnke K; Du J; de Dios A; Beckmann RP; Buchanan S; Lallena MJ
Oncotarget; 2017 Sep; 8(41):69493-69507. PubMed ID: 29050219
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
3. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
[TBL] [Abstract][Full Text] [Related]
5. The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models.
Hu W; Wang L; Luo J; Zhang J; Li N
Breast Cancer (Dove Med Press); 2023; 15():899-912. PubMed ID: 38090281
[TBL] [Abstract][Full Text] [Related]
6. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
[TBL] [Abstract][Full Text] [Related]
8. Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.
Sun CY; Talukder M; Cao D; Chen CW
Front Pharmacol; 2022; 13():829759. PubMed ID: 35814226
[TBL] [Abstract][Full Text] [Related]
9. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.
Dhir T; Schultz CW; Jain A; Brown SZ; Haber A; Goetz A; Xi C; Su GH; Xu L; Posey J; Jiang W; Yeo CJ; Golan T; Pishvaian MJ; Brody JR
Mol Cancer Res; 2019 Oct; 17(10):2029-2041. PubMed ID: 31383722
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib for the treatment of breast cancer.
Kotake T; Toi M
Expert Opin Pharmacother; 2018 Apr; 19(5):517-524. PubMed ID: 29522364
[TBL] [Abstract][Full Text] [Related]
11. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
12. PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells.
Lee HJ; Kim KJ; Sung JH; Nam M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Kim JH
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899250
[TBL] [Abstract][Full Text] [Related]
13. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
[TBL] [Abstract][Full Text] [Related]
14. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.
Kosovec JE; Zaidi AH; Omstead AN; Matsui D; Biedka MJ; Cox EJ; Campbell PT; Biederman RWW; Kelly RJ; Jobe BA
Oncotarget; 2017 Nov; 8(59):100421-100432. PubMed ID: 29245989
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
18. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors.
Small J; Washburn E; Millington K; Zhu J; Holder SL
Oncotarget; 2017 Nov; 8(56):95116-95134. PubMed ID: 29221116
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
20. Profile of abemaciclib and its potential in the treatment of breast cancer.
Martin JM; Goldstein LJ
Onco Targets Ther; 2018; 11():5253-5259. PubMed ID: 30214230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]